FILTER
LATEST INTERVIEWS
Francisco Errazuriz & Jorge Rios
CEO & COMMERCIAL MANAGER, SKC MAQUINARIAS CHILE
SKC Maquinarias Chile believes that adaptability and technology will be fundamental in servicing its mining clients.
Eduardo Ruiz
GENERAL MANAGER - PERU, AMPHOS 21
Amphos21 sees great potential to develop and incorporate new services and product lines in Peru.
Jeff Olsen
CEO, BOART LONGYEAR
Boart Longyear in Peru discusses how its technological innovations can benefit drilling.
Simao Antunes
GENERAL MANAGER SOUTH AMERICA, HOFMANN ENGINEERING
Hofmann Engineering explains how it is expanding into South America.
Ramin Cyrus
VICE PRESIDENT MARKETING, LONZA CAPSULES AND HEALTH INGREDIENTS
Lonza Capsules and Health Ingredients comments on market trends.
Javier Schmal
VICE PRESIDENT – LATIN AMERICA, MARTIN ENGINEERING
Martin Engineering explains how it is applying technology to improve its product line.
Dustin Angelo
PRESIDENT, CEO AND CO-FOUNDER, NOVAMERA INC.
Novamera explains how its drilling technology provides a pathway for companies to start projects that were previously was not economically feasible, or to add existing mineral resources outside of their mine plan to their operations.
Errol Smart
MANAGING DIRECTOR & CEO, ORION MINERALS
Orion Minerals explains its vision to grow into a sustainable mid-tier, green metal producer in the near future.
André Snyman
MANAGING DIRECTOR, WALVIS BAY SALT HOLDINGS
Walvis Bay Salt Holdings explains what is needed to successfully grow industry in Namibia.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
